INTRODUCTION
============

*Acinetobacter baumannii* is an important nosocomial pathogen ([@B1]-[@B6]). Carbapenem is a preferred drug of choice for the treatment of multidrug-resistant *A. baumannii*. However, carbapenem-resistant strains have now emerged around the world ([@B2]). Prevalence of carbapenem-resistant *A. baumannii* varies in different countries; in Korea, the resistance rate of *A. baumannii* against carbapenem was reported as 31.7% or 34.9% ([@B7]).

*A. baumannii* may cause various clinical manifestations ranging from colonization to septic shock, and *A. baumannii* bacteremia-associated mortality rate is reported to be as high as 17%-62% ([@B8]-[@B10]). Initiation of effective empirical antimicrobial treatment might be important for reducing *A. baumannii* bacteremia-associated mortality. However, in Korea, initiation of broad spectrum antibiotic treatment with antibiotics such as carbapenem or colistin is difficult because of insurance problems ([@B11], [@B12]). Because the severity of underlying disease could affect the outcomes in patients with *A. baumannii* bacteremia, it is not yet clear whether immediate and appropriate antimicrobial therapy as proper dose and administration route can affect these outcomes ([@B12], [@B13]). Because of the presence of limited therapeutic options for carbapenem-resistant *A. baumannii* (CRAB), it is important to understand the factors responsible for the development of carbapenem-resistance and the risk factors associated with mortality. In this study, we investigated the factors associated with acquisition of CRAB in patients with *A. baumannii* bacteremia; and the predictors associated with 14-day mortality. Our study especially focused on the impact of early and appropriate antimicrobial treatment after obtaining culture results.

MATERIALS AND METHODS
=====================

Study design
------------

A retrospective study was performed from June 2007 to June 2010 at a tertiary care hospital with 1,200 beds in Korea. All patients over 16-yr old from whom *A. baumannii* was isolated from at least one set of blood cultures with definite clinical signs of infection were enrolled. Only the first bacteremic episode from each patient was included in this study. Antibiotic therapy was considered appropriate if the antibiotics administered via an appropriate route within 24 hr of blood culture results showed an in vitro effectiveness against isolated strains, and if the dosage was adequate according to the current guidelines. Infection was assessed according to \"Centers for Disease Control and Prevention\" criteria, and patients were considered infected when *A. baumannii* was isolated from a sterile site in patients with definite clinical signs of infection ([@B14]). Prior antibiotics treatment was defined as the use of systemic antibiotics for at least 7 days within the preceding 28 days. For better understanding of the patients\' baseline status, we assessed the APACHE II score before bacteremia on the date of admission. We used 14-day in-hospital mortality as the main outcome for assessment of mortality for patients with serious conditions due to bacteremia.

Microbiological examination
---------------------------

Identification of *A. baumannii* in blood samples was performed using a VITEK^R^2 automated system (bioMérieux, Marcy l\'Etoile, France). Susceptibility results were interpreted according to guidelines established by the Clinical and Laboratory Standards Institute ([@B15]). CRAB was defined as non-susceptible to meropenem and/or imipenem in vitro, and isolates with intermediate resistance were regarded as resistance.

Statistically analysis
----------------------

Student\'s t-test was used for analysis of continuous variables, and the chi-squared test or Fisher\'s exact test was used for categorical variables and Student\'s t test or the Mann-Whitney U test for continuous variables. We analyzed the risk factors associated with mortality using univariate and multivariate logistic regression analyses. Survival curves were prepared using the Kaplan-Meier method with log-rank test. Statistical analysis was performed using SPSS 13.0 and a *P* value \< 0.05 was considered statistically significant.

Ethics statement
----------------

This study was approved by the institutional review board of Seoul St. Mary\'s Hospital (Protocol No; KC10OISI0070). Informed consent was waived by the board. All the data collected during this study were kept confidential.

RESULTS
=======

A total of 95 patients with *A. baumannii* bacteremia were included in this study. Demographic characteristics of these patients are shown in [Table 1](#T1){ref-type="table"}. The mean age of the patients was 58.4 ± 20.9 yr, and of the 95 patients, 53.7% were male. The mean length of stay before *A. baumannii* bacteremia was 30.2 ± 51.5 days. The presumed sources of bacteremia were respiratory tract (n = 28, 29.5%), vascular catheter (n = 24, 25.3%), intra-abdomen (n = 15, 15.8%), postoperative wounds (n = 8, 8.4%), urinary tract (n = 6, 6.3%), and other unknown sources (n = 8, 8.4%).

Fifty-three patients (55.8%) were infected with CRAB. Univariate analysis showed that the risk factors for acquisition of CRAB bacteremia were diabetes mellitus (OR 3.2, 95% CI 1.06-9.64; *P* = 0.04), dialysis (OR 4.23, 95% CI 1.11-15.9; *P* = 0.03) as an underlying disease, use of foley catheter (OR 2.91, 95% CI 1.26-6.73; *P* = 0.01), mechanical ventilation support (OR 4.6, 95% CI 1.66-12.77; *P* = 0.003), and prior use of cephalosporin (OR 3.81, 95% CI 1.62-8.96; *P* = 0.002) or carbapenem (OR 19.3, 95% CI 4.21-87.9; *P* = 0.001). By multivariate analysis, diabetes mellitus as an underlying disease (OR 4.51, 95% CI 1.16-14.8; *P* = 0.03) and prior use of carbapenem (OR 14.8, 95% CI 2.76-79.5; *P* = 0.002) were independently associated with CRAB bacteremia ([Table 2](#T2){ref-type="table"}).

The overall infection-related 14-day mortality in patients with *A. baumannii* bacteremia was 31.6% (30/95); infection-related 14-day mortality was higher in patients receiving inappropriate antimicrobial therapy than in patients receiving appropriate therapy (59.5% \[22/37\] vs 13.8% \[8/58\], *P* \< 0.05). The cumulative survival curves of the patients according to the appropriateness of antimicrobial therapy are shown in [Fig. 1](#F1){ref-type="fig"}. Univariate analysis showed that the risk factors for infection-related 14-day mortality in patients with *A. baumannii* bacteremia were central venous catheter (OR 4.02, 95% CI 1.37-11.83; *P* = 0.01), mechanical ventilatoin (OR 5.77, 95% CI 2.22-15.02; *P* \< 0.001), high APACHE II score (OR 4.01, 95% CI 1.39-11.4; *P* = 0.01), septic shock (OR 5.61, 95% CI 2.13-14.7; *P* \< 0.001), carbapenem-resistance (OR 9.14, 95% CI 2.86-29.2; *P* \< 0.001), pneumonia as a source of bacteremia (OR 5.05, 95% CI 1.94-13.0; *P* \< 0.001), and inappropriate antibiotic therapy (OR 6.58, 95% CI 2.53-17.1; *P* \< 0.001) ([Table 3](#T3){ref-type="table"}). Multivariate analysis showed that septic shock (OR 10.5, 95% CI 1.93-57.4; *P* = 0.006), carbapenem-resistance (OR 7.29, 95% CI 1.57-33.8; *P* = 0.01), pneumonia as a source of bacteremia (OR 5.29, 95% CI 1.07-26.1; *P* = 0.04), and inappropriate antimicrobial therapy (OR 8.05, 95% CI 1.65-39.2; *P* = 0.009) were the independent risk factors for 14-day mortality ([Table 3](#T3){ref-type="table"}). In sub-analysis of the CRAB group, patients receiving inappropriate antimicrobial therapy showed a higher mortality than those receiving appropriate therapy (67.9% \[19/28\] vs 28.0% \[7/25\], *P* = 0.004). In the non-CRAB group, 33 patients received appropriate therapy and 97% of the patients had survived for 14 days after the onset of bacteremia.

DISCUSSION
==========

*A. baumannii* is usually a healthcare-associated pathogen and is emerging as a cause of numerous global outbreaks ([@B1], [@B2]). Antimicrobial resistance recently has emerged as an important problem. Carbapenem is widely used for the treatment of multidrug-resistant *A. baumannii* infections, however, reports of CRAB are also increasing worldwide.

Previous studies have showed that factors associated with mortality in patients with *A. baumannii* infection are septic shock, age, severity of the underlying disease, and mechanical ventilation ([@B16]-[@B18]). Delay in receiving empirical antimicrobial therapy has an adverse effect on clinical outcomes, however, some studies have shown that severity of illness is a more important factor for mortality than empirical therapy in hospital-acquired pneumonia caused by *A. baumannii* ([@B12], [@B19]). Moreover, in Korea, use of broad spectrum antibiotics prior to the isolation of multidrug-resistant strains is limited.

Our study revealed that independent risk factors associated with 14-day mortality in patients with *A. baumannii* bacteremia included septic shock, carbapenem-resistance, pneumonia as a source of bacteremia and inappropriate antibiotic therapy. This study evaluated the clinical outcomes in patients with *A. baumannii* bacteremia according to the inappropriateness of antibiotics (i.e., antibiotics that were not active in vitro and those that were administered as an improper dose or through an improper route) after obtaining the blood culture results. Our data suggest that early administration of appropriate antimicrobial therapy showed improved outcomes in patients with CRAB bacteremia, although underlying status played an important role in clinical outcome.

Studies have shown that APACHE II score is useful for the estimation of prognosis in *Acinetobacter* pneumonia ([@B19], [@B20]). In our study, a high APACHE II score was associated with mortality by univariate analysis; however this was not identified as an independent risk factor by multivariate analysis. This may be because of several reasons. First, some information, such as that on sepsis and mechanical ventilation, was not included while determining this score. Second, we assessed the APACHE II score before the occurrence of bacteremia on the date of admission, in order to best reflect the patients\' baseline status. Our study also showed that septic shock at the time of bacteremia was an independent risk factor for mortality. This finding suggested that a combination of other parameters, including the APACHE II score, is necessary for the evaluation of morbidity in patients with bacteremia.

The effect of antibiotic resistance on mortality is controversial. Some studies have reported that antibiotic resistance has an adverse impact on the mortality rates in patients with *A. baumannii* bacteremia ([@B1], [@B21]). One study reported that mortality in patients with multidrug-resistant *A. baumannii* infection in surgical intensive care units did not differ significantly from that in patients with non-multidrug-resistant *A. baumannii* infection. However, the study did not include patients who were simply bacteremic ([@B6]). Our results showed that carbapenem resistance was independently associated with mortality. However, patients with CRAB bacteremia had a higher APACHE II score (14.4 ± 7.7 vs 10.4 ± 6.1, *P* = 0.005) and received a more inappropriate antibiotic treatment (52.8% \[28/53\] vs 21.4% \[9/42\], *P* = 0.002) than those with non-CRAB bacteremia. CRAB bacteremia usually occurs in patients with severe illness and in patients with a high probability of receiving inappropriate antimicrobial therapy, which then negatively affect the outcomes.

Results from the present study also showed that factors for acquisition of CRAB included diabetes mellitus as an underlying disease and a prior exposure to carbapenem. Some studies have reported that prior use of carbapenem, third-generation cephalosporins and fluoroquinolones are independent risk factors for the acquisition of multidrug resistant *A. baumannii* ([@B22], [@B23]). Selective pressure exerted by use of broad spectrum antibiotics, such as carbapenem, leads to the emergence of multidrug-resistant *A. baumannii*. Therefore, we consider multidrug resistance in patients with *A. baumannii* bacteremia who showed particularly severe illness, and who had recently received carbapenem. In order to decrease acquisition of CRAB, judicious use of carbapenem is important.

Our study had some limitations, including the retrospective design, which was not randomized. A small number of patients were enrolled from a single center. Furthermore, we could not judge the appropriateness of the empirical antibiotic treatment in this study. It was rare that patients with CRAB bacteremia received colistin empirically, because of insurance or restriction of broad spectrum antibiotics for policy of antibiotics control. However, our study should encourage clinicians not to delay definite antimicrobial treatment in patients with *A. baumannii* bacteremia.

In conclusion, patients with *A. baumannii* bacteremia receiving early and appropriate antimicrobial therapy are expected to show favorable outcomes, although the status of underlying disease also plays an important role in the clinical outcomes.
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Clinical characteristics of patients with *Acinetobacter baumannii* bacteremia
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CRAB, carbapenem-resistant *Acinetobacter baumannii*.
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Risk factors for acquisition of carbapenem resistant *Acinetobacter baumannii* bacteremia
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CRAB, carbapenem-resistant *Acinetobacter baumannii*.
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Risk factors associated with 14-day mortality in patients with *Acinetobacter baumannii* bacteremia
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OR, odds ratio; CI, confidential interval; CR, carbapenem-resistance.
